These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 32202631)

  • 1. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.
    Einsele H; Ljungman P; Boeckh M
    Blood; 2020 May; 135(19):1619-1629. PubMed ID: 32202631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
    Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
    Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
    Li L; Wang Y; Yan CH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients.
    Ciáurriz M; Beloki L; Zabalza A; Bandrés E; Mansilla C; Pérez-Valderrama E; Lachén M; Rodríguez-Calvillo M; Ramírez N; Olavarría E
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.
    Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC
    Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.
    Camargo JF; Anderson AD; Rosa R; Kimble E; Komanduri KV; Morris MI
    Transpl Infect Dis; 2019 Apr; 21(2):e13054. PubMed ID: 30689300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytomegalovirus infections following allogeneic hematopoietic stem cell transplantation: prophylaxis and treatment].
    Katayama Y; Iwato K
    Rinsho Ketsueki; 2019; 60(6):635-645. PubMed ID: 31281156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.
    Serio B; Rosamilio R; Giudice V; Pepe S; Zeppa P; Esposiito S; Pezzullo L; Rocco M; Montuori N; Selleri C
    Infez Med; 2012; 20 Suppl 2():26-34. PubMed ID: 23042003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ganciclovir treatment failure in adult allogeneic hematopoietic stem cell transplant recipients with cytomegalovirus infection--a single centre experience].
    Vejražková E; Hubáček P; Kutová R; Plíšková L; Košťál M; Štěpánová V; Zavřelová A; Radocha J; Malá E; Žák P
    Epidemiol Mikrobiol Imunol; 2015 Sep; 64(3):160-8. PubMed ID: 26448304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus Status and the Outcome of T Cell-Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.
    Verduyn Lunel FM; Raymakers R; van Dijk A; van der Wagen L; Minnema MC; Kuball J
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1883-1887. PubMed ID: 27470287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of cytomegalovirus infection after hematopoietic stem cell transplantation].
    Nishida T
    Rinsho Ketsueki; 2020; 61(9):1417-1423. PubMed ID: 33162544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of cytomegalovirus infection after hematopoietic stem cell transplantation].
    Mori T
    Rinsho Ketsueki; 2019; 60(9):1337-1340. PubMed ID: 31597861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
    El Chaer F; Mori N; Shah D; Oliver N; Wang E; Jan A; Doan V; Tverdek F; Tayar J; Ariza-Heredia E; Chemaly RF
    Antiviral Res; 2016 Nov; 135():91-96. PubMed ID: 27594527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status.
    Damlaj M; Khalid F; Alahmari B; Alaskar A; Ghazi S; Johani S; AlSaedy A; Bosaeed M; Alhejazi A; Al-Zahrani M
    Curr Res Transl Med; 2020 Aug; 68(3):131-137. PubMed ID: 32620466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation.
    Ke P; Bao X; Zhou J; Li X; Zhuang J; He X; Wu D; Zhang X; Ma X
    Hematology; 2020 Dec; 25(1):43-47. PubMed ID: 31906810
    [No Abstract]   [Full Text] [Related]  

  • 20. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data.
    Derigs P; Radujkovic A; Schubert ML; Schnitzler P; Schöning T; Müller-Tidow C; Hegenbart U; Schönland SO; Luft T; Dreger P; Schmitt M
    Ann Hematol; 2021 Aug; 100(8):2087-2093. PubMed ID: 33270162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.